SCShiou-Sheng Chen

Shiou-Sheng Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shiou-Sheng Chen has a total of 219 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Variability in epilepsy polygenic risk prediction across Taiwanese population and clinical cohorts

    by Yi‐Syuan Ke, Meng‐Han Tsai, Chen‐Rui Ho, Che‐Yu Chou, Hung‐Hsin Chen, Remi Stevelink, Siwei Chen, Paul Chih‐Hsueh Chen, Yo‐Tsen Liu, Hsin Tung, et al.

    Objective: This study was undertaken to evaluate the predictive, stratification, and prognostic utility of polygenic risk scores (PRSs) for epilepsy in three Taiwanese cohorts comprising more than 7000 cases among more than 600 000 individuals, thereby addressing the limited evidence on PRS performance in non‐European populations. Methods: Leveraging results from the latest multiancestry genome‐wide association study (GWAS), we calculated PRS for all epilepsy, genetic generalized epilepsy (GGE), and focal epilepsy (FE) in two population cohorts—Taiwan Biobank–National Health Insurance Research Database (TWB‐NHIRD; N ~ 105 K) and Taiwan Precision Medicine Initiative (TPMI; N ~ 500 K), with cases defined by International Classification of Diseases codes and medications—and a clinically ascertained sample (Taiwanese subset of the Epi25 consortium [Epi25‐TWN]; N = 1140). PRS performance was assessed through lifetime risk models, age‐at‐onset stratifications, and phenome‐wide association studies (PheWASs). Results: PRS performance varied substantially by cohort, epilepsy type, and age at onset. GGE PRS had the strongest effect on GGE in Epi25‐TWN (per‐unit odds ratio [OR] = 1.65 [95% confidence interval (CI) = 1.24–2.23], p = 8.3 × 10 −4 , R 2 = 3.2%) but a weaker effect in TWB‐NHIRD and TPMI (ORs = 1.09–1.13 [95% CI = .98–1.23], p = .002–.057, R 2 = .14%–.22%). FE PRS effects on FE were more consistent but modest (ORs = 1.02–1.16 [95% CI = .97–1.33]). No prognostic value of PRS was found in predicting epilepsy from syncope or unspecified seizures. Individuals in the top 5% GGE PRS had >4‐fold increased risk in Epi25‐TWN but <1.5‐fold in the others. Restricting to earlier onset cases strengthened PRS signals in population cohorts, particularly for GGE, with PheWAS analysis revealing epilepsy‐specific associations. PRS effects were generally comparable but attenuated relative to European studies. Significance: Cohort design and phenotyping accuracy strongly influence the assessment of the predictive value of epilepsy PRS, highlighting caution in clinical interpretation. Incorporating richer phenotypic data and more diverse GWASs will be crucial to enhancing its applicability and clinical potential.

  • Open Access

    Relationships between the Characters of Questionnaire Respondents with the Individual Testlets and Items of the Questionnaires of Patients of Bidirectional Referrals between National Taiwan University Hospital and Taipei City Hospital, Zhongxiao Campus

    by Mu-Jung Kao, Shiou-Sheng Chen, Jia-Ren Tsai, Dachen Chu, Jenn Yeu Wang

    Background: The usage of questionnaires to assess the satisfaction of patients is the modern advance in the revolution of health care systems. We aimed to correlate the characteristics of bidirectional referral patients who responded effectively to bidirectional referral interventions with the individual testlets and items of the questionnaires Methods: Based on the patient‘s age groups, weeks of hospitalization, gender, educational levels, identities of the bi-directional referral questionnaire respondents, we analyzed the relationships between these characters of the patients and average score for each testlet and the response score of each item and total scores of this hospital and bidirectional referral. Results: Levels of educational attainments of patients were found to influence and low level significantly and positively correlate with item 1 of Environment and item 29 of Process. Categories of patients' age groups were noted to affect and low level significantly and positively associated with item 12 of Administrative Efficiency, item 29 and 27 of Process, item 24 of Attitude, item 41 and 42 of overall evaluation. Conclusion:While interpreting the bidirectional referral questionnaires data, we should take into account the influence of age and levels of education.

  • Open Access

    Deleterious Variants Contribute Minimal Excess Risk in Large-Scale Testing

    by Yen-Tsung Huang, En-Yu Lai, Jia-Ying Su, Hsueh-Ju Lu, Yen-Lin Chen, Jer-Yuarn Wu, Chun-Yu Wei, Ling-Hui Li, Null- Fann, Hsin-Chou Yang, et al.

    DNA sequencing of patients with rare disorders has been highly successful in identifying “causal variants” for numerous conditions. However, there are many reports of healthy individuals who harbor these deleterious variants, leading to the concept of incomplete penetrance and doubt about the utility of genetic testing in clinical practice and population screening. As the deleterious variants are rare, the penetrance of these variants in the population is largely unknown. We analyzed the genetic and clinical data from 486,956 participants of the Taiwan Precision Medicine Initiative (TPMI) to determine the risk difference between those with and without deleterious variants. In all, we analyzed 292 disease-relevant variants and their clinical outcomes to assess their association. We found that only 15 variants show a risk difference exceeding 5% between those with or without the variants. In essence, 87.3% of deleterious variants exhibit minimal risk differences, suggesting a limited impact on the individual and population levels. Our analysis revealed increasing trends with age in six cardiovascular and degenerative diseases and bell-shaped trends in two cancers. Additionally, we identified three clinical outcomes exhibiting a dose-response relationship with the number of deleterious variants. Our findings show that large-scale testing of deleterious variants found in the literature is not warranted, except for those exhibiting large disease risk differences.


  • Open Access

    In Vivo Effect of Halicin on Methicillin-Resistant Staphylococcus aureus-Infected Caenorhabditis elegans and Its Clinical Potential

    by Li-Ting Kao, Tsung-Ying Yang, Wei-Chun Hung, Wei-Te Yang, Pu He, Bo-Xuan Chen, Yu-Chi Wang, Shiou-Sheng Chen, Yu-Wei Lai, Hsian-Yu Wang, et al.

    Recently, the high proportion of methicillin-resistant Staphylococcus aureus infections worldwide has highlighted the urgent need for novel antibiotics to combat this crisis. The recent progress in computational techniques for use in health and medicine, especially artificial intelligence (AI), has created new and potential approaches to combat antibiotic-resistant bacteria, such as repurposing existing drugs, optimizing current agents, and designing novel compounds. Halicin was previously used as a diabetic medication, acting as a c-Jun N-terminal protein kinase (JNK) inhibitor, and has recently demonstrated unexpected antibacterial activity. Although previous efforts have highlighted halicin’s potential as a promising antibiotic, evidence regarding its effectiveness against clinical strains remains limited, with insufficient proof of its clinical applicability. In this study, we sought to investigate the antibacterial activity of halicin against MRSA clinical strains to validate its clinical applicability, and a C. elegans model infected by MRSA was employed to evaluate the in vivo effect of halicin against MRSA. Our findings revealed the antibacterial activity of halicin against methicillin-resistant S. aureus clinical strains with MICs ranging from 2 to 4 µg/mL. Our study is also the first work to evaluate the in vivo effect of halicin against S. aureus using a C. elegans model, supporting its further development as an antibiotic.


  • Open Access

    Precision health in Taiwan: A data-driven diagnostic platform for the future of disease prevention

    by Wesley Wei-Wen Hsiao, Jui-Chu Lin, Chien-Te Fan, Saint Shiou-Sheng Chen

    “Precision medicine” has revolutionized how we respond to diseases by using an individual’s genomic data and lifestyle and environment-related information to create an effective personalized treatment. However, issues surrounding regulations, medical insurance payments and the use of patients’ medical data, have delayed the development of precision medicine and made it difficult to achieve “true” personalization. We therefore recommend that precision medicine be transformed into precision health: a novel and generalized platform of tools and methods that could prevent, manage, and treat disease at a population level. “Precision health,” one of six core strategic industries highlighted in Taiwan’s vision for 2030, uses various physiological data, genomic data, and external factors, to develop unique “preventative” solutions or therapeutic strategies. For Taiwan to implement precision health, it has to address three challenges: (1) the high-cost issue of precision health; (2) the harmonization issues surrounding integration and transmission of specimen and data; (3) the legal issue of combining information and communications technology (ICT) with Artificial Intelligence (AI) for medical use. In this paper, we propose an innovative framework with six recommendations for facilitating the development of precision health in Taiwan, including a novel model of precise telemedicine with AI-aided technology. We then describe how these tools can be proactively applied in early response to the COVID-19 crisis. We believe that precision health represents an important shift to more proactive and preventive healthcare that enables people to lead healthier lives.


  • Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2

    by Szu Lee, Shih-Wei Wang, Chen-Lin Yu, Huai-Ching Tai, Juei-Yu Yen, Yu-Lien Tuan, Hsueh-Hsiao Wang, Yi-Ting Liu, Shiou-Sheng Chen, Hsueh-Yun Lee


  • Open Access

    Significant relationship between parameters measured by transrectal color Doppler ultrasound and sexual dysfunction in patients with BPH 12 months after TURP

    by Li K. Chen, Yu W. Lai, Li P. Chiu, Saint Shiou-Sheng Chen

    Background: A link between sexual dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) has been noticed. Transurethral resection of the prostate (TURP) remains the standard treatment for symptomatic BPH, whether TURP causes sexual dysfunction is still uncertain. In this retrospective study, we investigated the relationship between parameters measured by color Doppler ultrasound (CDU) and sexual dysfunction in patients with BPH 12 months after TURP. Methods: The parameters include presumed circle area ratio (PCAR), maximal horizontal area of seminal vesicles (MHA), resistive index of the prostate (RIP), and peak systolic velocity in the flaccid penis (PSV). The international prostate symptom score was used to evaluate the lower urinary tract symptoms and the five-item version of the International Index of Erectile Function was used to evaluate sexual function before and after TURP. Results: Of the 103 patients without sexual dysfunction before TURP, 11 (10.7%) had erectile dysfunction (ED) after TURP. These 11 patients had significantly lower PCAR, RIP, PSV and MHA than those without ED. The patients with retrograde ejaculation after TURP had significantly lower PCAR than those without retrograde ejaculation, and the patients with premature ejaculation after TURP had significantly lower MHA than those without premature ejaculation. Comparing the parameters between baseline and after TURP, PCAR, RIP, and MHA decreased significantly in the patients with sexual dysfunction, but no significant differences were noted in the patients without sexual dysfunction after TURP. Conclusions: More extended TURP can lead to a higher incidence of ED and retrograde ejaculation in BPH patients without sexual dysfunction before TURP. Patients with a lower volume of seminal vesicles after TURP may have a higher incidence of premature ejaculation.


  • Melatonin impedes prostate cancer metastasis by suppressing MMP‐13 expression

    by Shih‐Wei Wang, Huai‐Ching Tai, Chih‐Hsin Tang, Liang‐Wei Lin, Tien‐Huang Lin, An‐Chen Chang, Po‐Chun Chen, Yi‐Hsuan Chen, Po‐Chuan Wang, Yu‐Wei Lai, et al.

    Prostate cancer has high metastatic potential. Men with higher urinary levels of the sleep hormone melatonin are much less likely to develop advanced prostate cancer compared with men with lower levels of melatonin. Melatonin has shown anticancer activity in experimental investigations. Nevertheless, the therapeutic effect of melatonin in metastatic prostate cancer has largely remained a mystery. Analyses of Gene Expression Omnibus data and human tissue samples indicated that levels of matrix metallopeptidase 13 (MMP‐13) expression are higher in prostate cancer patients than in healthy cancer‐free individuals. Mechanistic investigations revealed that melatonin inhibits MMP‐13 expression and the migratory and invasive capacities of prostate cancer cells via the MT1 receptor and the phospholipase C, p38, and c‐Jun signaling cascades. Importantly, tumor growth rate and metastasis to distant organs were suppressed by melatonin in an orthotopic prostate cancer model. This is the first demonstration showing that melatonin impedes metastasis of prostate cancer by suppressing MMP‐13 expression in both in vitro and in vivo models. Thus, melatonin is promising in the management of prostate cancer metastasis and deserves to undergo clinical investigations.


  • Open Access

    Phomaketide A Inhibits Lymphangiogenesis in Human Lymphatic Endothelial Cells

    by Huai-Ching Tai, Tzong-Huei Lee, Chih-Hsin Tang, Lei-Po Chen, Wei-Cheng Chen, Ming-Shian Lee, Pei-Chi Chen, Chih-Yang Lin, Chih-Wen Chi, Yu-Jen Chen, et al.

    Lymphangiogenesis is an important biological process associated with cancer metastasis. The development of new drugs that block lymphangiogenesis represents a promising therapeutic strategy. Marine fungus-derived compound phomaketide A, isolated from the fermented broth of Phoma sp. NTOU4195, has been reported to exhibit anti-angiogenic and anti-inflammatory effects. However, its anti-lymphangiogenic activity has not been clarified to date. In this study, we showed that phomaketide A inhibited cell growth, migration, and tube formation of lymphatic endothelial cells (LECs) without an evidence of cytotoxicity. Mechanistic investigations revealed that phomaketide A reduced LECs-induced lymphangiogenesis via vascular endothelial growth factor receptor-3 (VEGFR-3), protein kinase Cδ (PKCδ), and endothelial nitric oxide synthase (eNOS) signalings. Furthermore, human proteome array analysis indicated that phomaketide A significantly enhanced the protein levels of various protease inhibitors, including cystatin A, serpin B6, tissue factor pathway inhibitor (TFPI), and tissue inhibitor matrix metalloproteinase 1 (TIMP-1). Importantly, phomaketide A impeded tumor growth and lymphangiogenesis by decreasing the expression of LYVE-1, a specific marker for lymphatic vessels, in tumor xenograft animal model. These results suggest that phomaketide A may impair lymphangiogenesis by suppressing VEGFR-3, PKCδ, and eNOS signaling cascades, while simultaneously activating protease inhibitors in human LECs. We document for the first time that phomaketide A inhibits lymphangiogenesis both in vitro and in vivo, which suggests that this natural product could potentially treat cancer metastasis.


  • The hOGG1 Ser326Cys polymorphism and male subfertility in Taiwanese patients with varicocele

    by S. S.‐S. Chen, L.‐P. Chiu

    To investigate the association between the human 8‐oxoguanine DNA glycosylase 1 (hOGG1) gene Ser326Cys polymorphism and male subfertility in Taiwanese patients with varicocele, we made a prospective study. Ninety young male patients with varicocele (group 1), 50 young male patients with subclinical varicocele (group 2) and 30 normal young male patients without varicocele (group 3) were recruited in this study. The hOGG1 null homozygous genotype (Cys/Cys) and the occurrence of a 4,977‐bp deletion in mitochondrial DNA and mitochondrial copy number in spermatozoa were determined by polymerase chain reaction. The 8‐hydroxy‐2′‐deoxyguanosine (8‐OHdG) content of DNA in the spermatozoa was measured using high‐performance liquid chromatography, and total antioxidant capacity (TAC) of seminal plasma was detected electrochemically. The rates of male subfertility were 31.1% (28/90) in group 1 and 22% (11/50) in group 2. Of 39 subfertile men, 74.4% (29/39) had the hOGG1 Cys/Cys genotype. Patients in groups 1 and 2 with hOGG1 Cys/Cys genotype had significantly higher 8‐OHdG content in sperm DNA, lower mitochondrial copy number in spermatozoa and lower TAC in seminal plasma than those with Ser/Ser or Ser/Cys genotype. Clinicians should pay more attention to patients with varicocele with the hOGG1 Cys/Cys genotype.